References
1. Neunert C, Terrell DR, Arnold DM, et al. American Society of
Hematology 2019 guidelines for immune thrombocytopenia. Blood
Adv . 2019;3(23):3829-3866. doi:10.1182/BLOODADVANCES.2019000966
2. Provan D, Arnold DM, Bussel JB, et al. Updated international
consensus report on the investigation and management of primary immune
thrombocytopenia. Blood Adv . 2019;3(22):3780-3817.
doi:10.1182/BLOODADVANCES.2019000812
3. Jayabose S, Levendoglu-Tugal O, Ozkaynkak MF, Visintainer P, Sandoval
C. Long-term outcome of chronic idiopathic thrombocytopenic purpura in
children. J Pediatr Hematol Oncol . 2004;26(11):724-726.
doi:10.1097/00043426-200411000-00007
4. Terrell DR, Neunert CE, Cooper N, et al. Immune Thrombocytopenia
(ITP): Current Limitations in Patient Management. Medicina
(Kaunas) . 2020;56(12):1-10. doi:10.3390/MEDICINA56120667
5. Djulbegovic B, Cohen Y, Portielje JEA, Westendorp RGJ, Kluin-Nelemans
HC, Brand A. The natural history of refractory idiopathic
thrombocytopenic purpura. Blood . 2001;98(7):2282-2283.
doi:10.1182/BLOOD.V98.7.2282
6. Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J. A
systematic approach to searching: an efficient and complete method to
develop literature searches. J Med Libr Assoc .
2018;106(4):531-541. doi:10.5195/JMLA.2018.283
7. Nama N, Barrowman N, O’Hearn K, Sampson M, Zemek R, McNally JD.
Quality control for crowdsourcing citation screening: the importance of
assessment number and qualification set size. J Clin Epidemiol .
2020;122:160-162. doi:10.1016/J.JCLINEPI.2020.02.009
8. Khera S, Pramanik SK, Yanamandra U, Mishra K, Kapoor R, Das S.
Dapsone: An Old but Effective Therapy in Pediatric Refractory Immune
Thrombocytopenia. Indian J Hematol Blood Transfus .
2020;36(4):690-694. doi:10.1007/S12288-020-01286-9
9. Ay Y, Karapinar TH, Oymak Y, et al. Retrospective analysis of
rituximab therapy and splenectomy in childhood chronic and refractory
immune thrombocytopenic purpura. Blood Coagul Fibrinolysis .
2016;27(4):431-435. doi:10.1097/MBC.0000000000000488
10. Leblebisatan G, Kilinc Y, Cil M, Sasmaz İ, Ozkan A. Eltrombopag For
Immune Thrombocytopenic Children in a Single Region. Indian J
Hematol Blood Transfus . 2018;34(4):707-710.
doi:10.1007/S12288-018-0928-Y
11. Sezgin Evim M, Baytan B, Güneş AM. Childhood Immune
Thrombocytopenia: Long-term Follow-up Data Evaluated by the Criteria of
the International Working Group on Immune Thrombocytopenic Purpura.Turkish J Haematol Off J Turkish Soc Haematol . 2014;31(1):32-39.
doi:10.4274/TJH.2012.0049
12. Adly AAM, Ragab IA, Ismail EAR, Farahat MM. Evaluation of the
immature platelet fraction in the diagnosis and prognosis of childhood
immune thrombocytopenia. Platelets . 2015;26(7):645-650.
doi:10.3109/09537104.2014.969220
13. Matsubara K, Takahashi Y, Hayakawa A, et al. Long-term follow-up of
children with refractory immune thrombocytopenia treated with rituximab.Int J Hematol . 2014;99(4):429-436. doi:10.1007/S12185-014-1541-Y
14. Pasquet M, Aladjidi N, Guiton C, et al. Romiplostim in children with
chronic immune thrombocytopenia (ITP): the French experience. Br J
Haematol . 2014;164(2):266-271. doi:10.1111/BJH.12609
15. Grace RF, Long M, Kalish LA, Neufeld EJ. Applicability of 2009
international consensus terminology and criteria for immune
thrombocytopenia to a clinical pediatric population. Pediatr Blood
Cancer . 2012;58(2):216-220. doi:10.1002/PBC.23112
16. Rao VK, Price S, Perkins K, et al. Use of rituximab for refractory
cytopenias associated with autoimmune lymphoproliferative syndrome
(ALPS). Pediatr Blood Cancer . 2009;52(7):847-852.
doi:10.1002/PBC.21965
17. Parodi E, Rivetti E, Amendola G, et al. Long-term follow-up analysis
after rituximab therapy in children with refractory symptomatic ITP:
identification of factors predictive of a sustained response. Br J
Haematol . 2009;144(4):552-558. doi:10.1111/J.1365-2141.2008.07487.X
18. Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune
reconstitution after rituximab therapy in pediatric patients with
chronic or refractory hematologic autoimmune cytopenias. Pediatr
Blood Cancer . 2008;50(4):822-825. doi:10.1002/PBC.21264
19. Oved JH, Lee CSY, Bussel JB. Treatment of Children with Persistent
and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of
Rituximab and Three 4-Day Cycles of Dexamethasone. J Pediatr .
2017;191:225-231. doi:10.1016/J.JPEDS.2017.08.036
20. Grace RF, Bennett CM, Ritchey AK, et al. Response to steroids
predicts response to rituximab in pediatric chronic immune
thrombocytopenia. Pediatr Blood Cancer . 2012;58(2):221-225.
doi:10.1002/PBC.23130
21. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of
terminology, definitions and outcome criteria in immune thrombocytopenic
purpura of adults and children: report from an international working
group. Blood . 2009;113(11):2386-2393.
doi:10.1182/BLOOD-2008-07-162503
22. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for
steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic
leukemia. Leukemia . 2002;16(10):2092-2095.
doi:10.1038/SJ.LEU.2402676
23. Paludo J, Abeykoon JP, Kumar S, et al. Dexamethasone, rituximab and
cyclophosphamide for relapsed and/or refractory and treatment-naïve
patients with Waldenstrom macroglobulinemia. Br J Haematol .
2017;179(1):98-105. doi:10.1111/BJH.14826
24. Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia
in adults and children: an evidence-based review. J Thromb
Haemost . 2013;11(11):1946-1953. doi:10.1111/JTH.12371
25. Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic
autoimmune thrombocytopenic purpura: a report of 66 cases. Br J
Haematol . 1997;97(2):336-339. doi:10.1046/J.1365-2141.1997.412687.X
26. Oo T, Hill QA. Disappointing response to dapsone as second line
therapy for primary ITP: a case series. Ann Hematol .
2015;94(6):1053-1054. doi:10.1007/S00277-014-2285-8
27. Patel AP, Patil AS. Dapsone for immune thrombocytopenic purpura in
children and adults. Platelets . 2015;26(2):164-167.
doi:10.3109/09537104.2014.886677
28. Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava
A. Dapsone for chronic idiopathic thrombocytopenic purpura in children
and adults–a report on 90 patients. Eur J Haematol .
2005;75(4):328-331. doi:10.1111/J.1600-0609.2005.00545.X
29. Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia.Blood . 2016;128(12):1547-1554. doi:10.1182/BLOOD-2016-03-603365
30. Amgen In. NPLATE® (romiplostim) for injection, for subcutaneous use
[prescribing information]. Published online 2018.
31. Corporation NP. PROMACTA® (eltrombopag) tablets, for oral use;
PROMACTA® (eltrombopag) for oral suspension [prescribing
information]. :2018.
32. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,
et al. The PRISMA 2020 statement: an updated guideline for reporting
systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
Appendix A. Electronic search strategies
Note: Note: Searches were conducted using an Ovid multi-database search
and duplicate records were removed online giving preference to MEDLINE,
then Embase, with no field preference. Lines 1-18 are optimized for
MEDLINE. Lines 19-37 are optimized for Embase and lines 38-56 are
optimized for CENTRAL. The next lines isolate the records to the
database the search was designed for, combine those sets and then remove
duplicate records and final isolate the records from each database again
so each can be downloaded and imported into the citation manager using a
database-specific import filter.
1. Purpura, Thrombocytopenic, Idiopathic/ or (ITP or Immune
thrombocytopen* or autoimmune thrombocytopen* or idiopathic
thrombocytopen* or werlhof*).ti,ab,kf.
2. (thrombocytopenia and (Evans or immune dysregulation or ALPS or CTLA4
or SLE or CVID)).mp.
3. inherited thrombocytopenia.ti,ab,kf.
4. (thrombocytopenia and inherited marrow failure).ti,ab,kf.
5. 1 or 2 or 3 or 4
6. (refractory or intractable or treatment-resistant or treatment
failure* or steroid-dependent or second line or chronic*).ti,ab,kf.
7. (child* or adolesc* or infan* or pediatr* or paediatr*).mp.
8. Terminology as Topic/ or (terminology or nomenclature or definition
or criteria or classification).mp.
9. Purpura, Thrombocytopenic, Idiopathic/di or (diagnosis or diagnostic
or workup or work-up).ti,ab,kf.
10. Purpura, Thrombocytopenic, Idiopathic/dh, dt, pc, rt, rh, th, cl
11. (therapy or therapeutics or treatment or management or intervention
or Second line or novel or Rituximab or romiplostim or
thrombopoietin-receptor agonists or immunosuppress* or glucocorticoid*
or prednisone or dexamethasone or eltrombopag or Mycophenolate Mophetil
or Mycophenolic acid or Azathioprine or Vincristine or vinblastine or
Cyclophosphamide or autologous stem cell or dexamethasone or
splenectomy*).mp.
12. 5 and 6 and 7 and (9 or 10 or 11)
13. 5 and 7 and 8
14. 12 or 13
15. limit 14 to yr=”2000 - 2021”
16. limit 15 to (english or french or german or polish or spanish)
17. limit 16 to (comment or editorial or letter)
18. 16 not 17
19. Idiopathic Thrombocytopenic Purpura/ or (ITP or Immune
thrombocytopen* or autoimmune thrombocytopen* or idiopathic
thrombocytopen* or werlhof*).ti,ab,kw.
20. (thrombocytopenia and (Evans or immune dysregulation or ALPS or
CTLA4 or SLE or CVID)).mp.
21. inherited thrombocytopenia.ti,ab,kw.
22. (thrombocytopenia and inherited marrow failure).ti,ab,kw.
23. or/19-22
24. (refractory or intractable or treatment-resistant or treatment
failure* or steroid-dependent or second line or chronic).ti,ab,kw.
25. (baby* or babies* or newborn* or infan* or neonat* or preschool* or
pre-school* or child* or pediatr* or paediatr* or teen* or adolescen* or
pediatr* or paediatr*).mp.
26. Nomenclature/ or (terminology or nomenclature or definition or
criteria or classification).mp.
27. Idiopathic Thrombocytopenic Purpura/di or (diagnosis or diagnostic
or workup or work-up).ti,ab,kw.
28. Idiopathic Thrombocytopenic Purpura/dt, pc, rt, rh, th, cl
29. (therapy or therapeutics or treatment or management or intervention
or Second line or novel or Rituximab or romiplostim or
thrombopoietin-receptor agonists or immunosuppress* or glucocorticoid*
or prednisone or dexamethasone or eltrombopag or Mycophenolate Mophetil
or Mycophenolic acid or Azathioprine or Vincristine or vinblastine or
Cyclophosphamide or autologous stem cell or dexamethasone or
splenectomy*).mp.
30. 23 and 24 and 25 and (27 or 28 or 29)
31. 23 and 25 and 26
32. 30 or 31
33. limit 32 to yr=”2000 - 2021”
34. limit 33 to (english or french or german or polish or spanish)
35. limit 34 to embase
36. limit 35 to (editorial or letter or ”review”)
37. 35 not 36
38. (ITP or Immune thrombocytopen* or autoimmune thrombocytopen* or
idiopathic thrombocytopen* or werlhof*).ti,ab,kw.
39. (thrombocytopenia and (Evans or immune dysregulation or ALPS or
CTLA4 or SLE or CVID)).mp.
40. (thrombocytopenia and inherited marrow failure).ti,ab,kw.
41. inherited thrombocytopenia.ti,ab,kw.
42. or/38-41
43. (refractory or intractable or treatment-resistant or treatment
failure* or steroid-dependent or second line or chronic).ti,ab,kw.
44. (baby* or babies* or newborn* or infan* or neonat* or preschool* or
pre-school* or child* or pediatr* or paediatr* or teen* or adolescen* or
pediatr* or paediatr*).mp.
45. (terminology or nomenclature or definition or criteria or
classification).mp.
46. (diagnosis or diagnostic or workup or work-up).ti,ab,kw.
47. (therapy or therapeutics or treatment or management or intervention
or Second line or novel or Rituximab or romiplostim or
thrombopoietin-receptor agonists or immunosuppress* or glucocorticoid*
or prednisone or dexamethasone or eltrombopag or Mycophenolate Mophetil
or Mycophenolic acid or Azathioprine or Vincristine or vinblastine or
Cyclophosphamide or autologous stem cell or dexamethasone or
splenectomy*).mp.
48. 42 and 43 and 44 and (46 or 47)
49. 42 and 44 and 45
50. 48 or 49
51. limit 50 to yr=”2000 - 2021”
52. 18 use medall
53. 37 use emczd
54. 51 use cctr
55. or/52-54
56. remove duplicates from 55
57. 56 use medall
58. 56 use emczd
59. 56 uce cctr